CHD1 and prostate carcinoma: UNC10142 selects for CHD1 against a panel of other methyllysine readers, and treatment of PTEN-deficient prostate cancer cells with UNC10142 leads to a dose-dependent reduction in viability, phenocopying genetic loss of CHD1.84